Progenics Pharmaceuticals Inc (USD)
PGNX
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range5.07 | 5.29
52-Wk Range3.42 | 6.37
Last Close5.10
Mkt Cap (m)440.32
Dividend yield-
ISINUS7431871067
Volume218,810
Exchange VenueNAS

Company Profile

Progenics Pharmaceuticals Inc is a biopharmaceutical company that develops innovative medicines and other technologies to identify, target and treat cancer. Its pipeline drugs include AZEDRA and 1095; 1404 and PyL; and imaging analysis tools.

Key Information
Price/Earning-
Price/Book7.87
Price/Sales18.78
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-
Debt/Equity-

Documents

Prospectus
en 08/08/2018
Annual Report
en 31/12/2018

Financials

Income Statement
USD201420152016201720182019
Revenue (m)449691216-
Operating Income (m)8-389-56-49-
Net Income (m)4-3911-51-68-
Basic EPS0.06-0.560.15-0.73-0.87-
Avg. Diluted Shares Outstanding (m)6870707078-
Balance Sheet
USD201420152016201720182019
Current Assets (m)1228314897144-
Non Current Assets (m)3948514925-
Total Assets (m)161131199146169-
Current Liabilities (m)710161523-
Total Liabilities (m)------
Total Equity (m)1259010563101-
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)14-4019-54-47-
Capital Expenditure (m)-1-4-1-
Figures are quoted in USD unless stated otherwise
0.04 (0.79%)
$
5.14
Last Price